Drug delivery platform will release medication for monthly dosing
August 30, 2019
Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.
New research indicates that for Texas providers and patients, the 2016 Food and Drug Administration’s (FDA) new labeling for the abortion drug mifepristone increased access options and brought the proportion of medication abortions in the state into alignment with national data.
Researchers with the University of North Carolina at Chapel Hill and the Centers for Disease Control and Prevention are examining a new drug delivery system that uses dolutegravir, an established HIV drug, in a potential longacting treatment and prevention system. The system has been tested in animal models.
The opioid addiction epidemic is introducing a new patient safety risk to healthcare facilities: the possibility of desperate and clever opioid addicts diverting medications from patients, which could leave the provider liable for any consequences.